Alnylam Pharmaceuticals (ALNY) Total Liabilities (2009 - 2026)

Alnylam Pharmaceuticals has reported Total Liabilities for 18 years, with the latest figure at $4.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 1.08% year-over-year to $4.1 billion; the trailing twelve-month figure through Mar 2026 stood at $4.1 billion (down 1.08% YoY), and the FY2025 full-year result was $4.2 billion, changed 0.1% from the prior year.
• Total Liabilities for Q1 2026 stood at $4.1 billion, down from $4.2 billion in the prior quarter.
• The five-year high for Total Liabilities was $4.6 billion in Q3 2025, with the low at $3.0 billion in Q1 2022.
• Historically, Total Liabilities has averaged $3.9 billion across 5 years, with a median of $4.0 billion in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 32.63% — and 2026, when it fell 1.08%.
• Alnylam Pharmaceuticals' Total Liabilities stood at $3.7 billion in 2022, then gained by 9.34% to $4.1 billion in 2023, then rose by 3.02% to $4.2 billion in 2024, then rose by 0.1% to $4.2 billion in 2025, then dropped by 2.94% to $4.1 billion in 2026.
• The last three Total Liabilities figures came in at $4.1 billion (Q1 2026), $4.2 billion (Q4 2025), and $4.6 billion (Q3 2025), per Business Quant data.